Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Naomi Eisenberger, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01671150
First received: July 11, 2012
Last updated: June 16, 2014
Last verified: June 2014
  Purpose

Depressive disorders occur at a high rate in patients with inflammatory disorders, with a point prevalence of 15-29%, which is two to three times greater than that observed in the general population. Substantial evidence has shown that inflammation and increases in proinflammatory cytokine activity play a critical role in the onset and perpetuation of depression and depressive symptoms (e.g. insomnia, fatigue) in those who are co-morbid for inflammatory disorders. Consistent with this, experimental work has shown that an inflammatory challenge can increase depressed mood in an otherwise healthy sample. Based on these findings, there has been a growing interest in whether inflammatory processes can contribute to depression in a causal manner and how these effects might occur.

Given the observation that inflammatory processes trigger social withdrawal, coupled with evidence that feelings of 'social disconnection' play a critical role in the onset and perpetuation of (non-inflammatory forms of) depression, it is surprising that the social psychological consequences of inflammation and their contribution to depression have not been more fully explored. Here, we suggest that inflammation may increase feelings of social disconnection and that these social psychological changes may be an important contributor to inflammation-associated depression. Indeed, preliminary data demonstrated that an experimentally-induced inflammatory challenge (endotoxin) led to increases in self-reported feelings of social disconnection (e.g., "I feel disconnected from others") in addition to increases in depressed mood. Aside from these findings, however, there are no studies that have explored the effect of inflammatory processes on social experience in humans. The over-arching objective of this proposal is to explore the experiential and neural correlates of inflammatory-induced changes in social experience (e.g., feelings of social disconnection), which may provide a critical missing link in understanding the relationship between inflammation and depression.

Participants (n=100) will be randomly assigned to receive either endotoxin or placebo and will then be monitored for the next six hours. Blood draws to assess cytokine levels as well as self-reported feelings of social disconnection and depressed mood will be collected hourly. In addition, at the time of peak cytokine response, participants will complete a neuroimaging session to examine the effect of inflammatory challenge on neural sensitivity to social rejection and social acceptance. It is hypothesized that endotoxin will increase feelings of social disconnection over time, and that the underlying neural sensitivities that give rise to these feelings (e.g., increased neural sensitivity to social rejection; decreased neural sensitivity to social acceptance) will contribute to inflammatory-induced depressed mood.


Condition Intervention Phase
Depression
Drug: endotoxin
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Change in depressed mood from baseline [ Time Frame: at baseline and then at 1,2,3,4,5,and 6 hours after drug administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Neural activity to negative and positive social feedback [ Time Frame: 2 hours after drug administration ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: March 2011
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo control
half of the participants will receive a placebo control
Drug: endotoxin
Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Active Comparator: Endotoxin (Inflammatory challenge) Drug: endotoxin
Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants will be required to be in good general health (as evaluated during the phone and in-person screening sessions described below), and to be between 18-50 years of age. All participants will be required to be fluent in English and to be right-handed.

Exclusion Criteria:

  • Following a structured telephone interview, prospective participants with the following conditions will not advance to the in-person screening session: claustrophobia or presence of metal in their body (relevant for the neuroimaging component of the study), pregnant or planning to become pregnant in the next 6 months, presence of chronic mental or physical illness, history of allergies, autoimmune, liver, or other severe chronic diseases, current and regular use of prescription medications, nightshift work or time zone shifts (> 3hrs) within the previous 6 weeks, or previous history of fainting during blood draws.

Furthermore, the absence of significant health problems or medication use history will be confirmed by an in-person screening session. Any participant who has any of the following conditions will be ineligible for the study: Medical conditions. (1) presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders; (2) presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders; (3) presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk; (4) presence of chronic infection, which may elevate proinflammatory cytokines; (5) presence of an acute infectious illness in the two weeks prior to an experimental session. Psychiatric Disorders. (6) current and/or lifetime history of a major Depressive Disorder or other DSM-IV psychiatric disorder (e.g. substance dependence) due to the known effects of major depression and/or substance dependence on inflammation. (Absence of a psychiatric diagnosis will be based on a structured psychiatric interview (Structured Clinical Interview for DSM-IV Diagnosis: SCID; First et al., 1996).) Medication and substance use. (7) current and/or past regular use of hormone-containing medications including steroids; (8) current and/or past regular use of non-steroid anti-inflammatory drugs; (9) current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists; (10) current and/or past regular use of analgesics such as opioids; (11) current and/or past regular use of psychotropic medications, including selective serotinergic reuptake inhibitors, antidepressants, anxiolytics, hypnotics, sedatives and barbiturates. Health factors. (12) current smokers or excessive caffeine users (>600 mg/day) because of known effects on proinflammatory cytokine levels; (13) body mass index (BMI) greater than 35, (14) shows evidence of drug use from a positive urine test, (15) has a positive pregnancy test, if female, or (16) shows any abnormalities on screening laboratory tests.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01671150

Locations
United States, California
UCLA Clinical & Translational Research Center
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Naomi Eisenberger, PhD University of California, Los Angeles
Principal Investigator: Michael Irwin, M.D. University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Naomi Eisenberger, Assistant Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01671150     History of Changes
Other Study ID Numbers: Endotoxin 2, R01MH091352
Study First Received: July 11, 2012
Last Updated: June 16, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of California, Los Angeles:
inflammation
depression
social cognition
neural activity

Additional relevant MeSH terms:
Depression
Depressive Disorder
Inflammation
Behavioral Symptoms
Mood Disorders
Mental Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on July 28, 2014